Blood Biomarkers for Screening of Alzheimer's Disease

Peking University First Hospital180 enrolled

Overview

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Alzheimer's Disease Blood Biomarkers

Interventions

Blood biomarkerDIAGNOSTIC_TEST

Blood biomarker

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 50 years; * AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects; * Signed informed consent form. Exclusion Criteria: * The presence of other disorders that can cause cognitive impairment; * Unable to cooperate with the completion of cognitive assessment; * Refusal to draw blood.

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Evaluate the diagnostic accuracy of blood biomarkers of Aβ42, Aβ40, Aβ42/Aβ40, P-Tau181, P-Tau217, GFAP and NfL.

Time frame: 2 years

Secondary Outcomes

Evaluate the diagnostic accuracy of a comprehensive model combined with core blood biomarkers and clinical information.

Time frame: 2 years

Central Contacts

Chen Zhang

CONTACT

86+83572462 chenzizm@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.